Health

Intuitive Surgical is 35% off its high as a court, J&J and Medtronic test its robot monopoly

A revived antitrust case, two newly cleared rivals and a return to the cardiac market it walked away from in 1998 all converge on the October 20 report. Hospitals pay the instrument-and-service lock-in; ISRG shareholders are carrying the de-rate.

Vincent JiangVincent Jiangthree-minute read
Share
A da Vinci Xi surgical robot with four instrument arms stands ready in an operating room
1 / 6Slide 1 of 6
A da Vinci Xi, the system behind Intuitive's 11,710-robot installed base. Intuitive reports third-quarter results on October 20.

A 35% de-rate on a 19% grower

Intuitive−1.42% — Intuitive, down 1.42 percent today closed at $391.95 on October 2, down 2.32% on the day and about 35% below its 52-week high of $603.88, valuing the company at $138.5 billion 1. The business underneath is not shrinking: second-quarter revenue rose 19% to $2.89 billion and net income reached $818 million 2. What the tape is repricing is the durability of an annuity that has gone essentially unchallenged for nearly 25 years 3.

The court reopened the blades aftermarket

On August 17 the Ninth Circuit revived Surgical Instrument Service's claims that Intuitive blocked third parties from refurbishing da Vinci instruments, refusing to apply the usual Kodak standard because near-100% market power changes how the aftermarket is judged 4. Intuitive petitioned the full court on September 29; the case, 25-1372, dates to March 2025 5. If refurbishing opens, hospitals get a cheaper second source for the highest-margin line, and the refurbisher gets the business.

The installed base is contestable for the first time

Johnson & Johnson's Ottava won De Novo authorization in July covering 10 general-surgery procedures, on a footprint 30-50% smaller than cart- and boom-mounted systems 3. Medtronic's−0.92% — Medtronic, down 0.92 percent today Hugo cleared the FDA for urology on December 3, 2025, with gynecology submissions advancing 6. Da Vinci still holds clearances across urology, gynecology and general surgery 6.

Cardiac is the offense as US growth slows

Intuitive was founded to chase robotic heart surgery and ran its first cardiac procedures in France and Germany in 1998, then spent decades on prostate and hernia volume instead 78. It is going back: a US cardiac clearance in January and a September 29 CE mark covering coronary bypass on da Vinci 5 78. The need is showing; US procedure growth slowed to 12% in the second quarter from 14% in the first, while international grew 20% 1.

US procedure growth slowed to 12% as international ran at 20%

0%5%10%15%20%US, Q1 2026US, Q2 2026International, Q2 202620%12%
Data
Da Vinci procedure growth, y/y
US, Q1 202614%
US, Q2 202612%
International, Q2 202620%
Year-over-year da Vinci procedure growth as reported: US slowed from 14% in the first quarter to 12% in the second, while international procedures grew 20%. Sources: [1].1

76 cents of every revenue dollar arrives after install

The installed base reached 11,710 systems, up 12%, on 468 placements 2. Instruments and accessories brought in $1.73 billion and services $472 million: 76 cents of every revenue dollar arrives after the robot is already installed 2. Non-GAAP gross margin ran at 70.0% 2.

Instruments and services are 76% of Intuitive's quarterly revenue

  • Instruments and accessories$1,730M59.9%
  • Services$472M16.3%
  • Systems and other$688M23.8%
Data
SliceValueShare
Instruments and accessories$1,730M59.9%
Services$472M16.3%
Systems and other$688M23.8%
Second-quarter 2026 revenue of $2.89 billion as reported: instruments and accessories ($1.73 billion) plus services ($472 million) are the installed-base annuity; systems and other is the balance. Sources: [2].2

Guidance held, and every broker target sits above the tape

Guidance held at 13.5% to 15.5%, toward the midpoint 2. A beat without a raise forecasts a slower second half, and targets were cut 9. A fourth pressure is demand-side: GLP-1 drugs are absorbing the bariatric patient pool 4. RBC set $575 on October 1, $183 above the tape 1; Piper Sandler called the decline unjustified at $470, UBS holds $500 and Bernstein trimmed to $685 4.

Every listed broker target sits $78 to $293 above the October 2 close

  • Estimate
$0$200$400$600$800Bernstein$685trimmed from $750 in AugustRBC$575UBS$500Piper Sandler$470Nasdaq close, 2 Oct 2026
Data
Value
Bernstein (estimate)$685
RBC (estimate)$575
UBS (estimate)$500
Piper Sandler (estimate)$470
Published analyst price targets for ISRG: Piper Sandler, UBS and Bernstein as of August 21, 2026, RBC as of October 1, 2026. Reference line is the Nasdaq closing price of $391.95 on October 2, 2026. Sources: [1], [4].1,4

Nothing filed yet shows erosion

The appeals court revived the claims without deciding them, and no filed number yet shows margin loss or lost placements 45. Even J&J's own bull case calls Ottava "still early" 10; the pessimist case assumes it scales slowly enough to lag MedTech margins 10. Hugo starts from a single specialty 6.

Three numbers settle it on October 20

Placements, US procedure growth, and instruments revenue per procedure 12. The en banc answer arrives more slowly, and nothing filed yet prices what an open refurbishing market would cost the blades.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading ISRG

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenAI lets clinicians prescribe from ChatGPT through Photon, moving pharmacy choice to patients

    For Evidenced, the healthcare venture firm that bets on U.S. regulatory tailwinds, the launch adds a second engine: market-driven distribution through OpenAI's clinician base. The free window through December 31 is the first adoption test for its portfolio company Photon.

    Health

    Kaiser's 1,200-scan trial found AI echo drafts matched clinicians and halved read time

    The Permanente Medical Group ran the randomized trial of EchoPrime itself and found the AI drafts matched clinician drafts while cutting cardiologist read time nearly in half. Days later it launched Permanentech, its own vehicle to commercialize clinical AI, so the buy-or-build question just got a benchmark.

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Subscribe to TheInference for free